卡培他滨联合铂类同步放化疗方案治疗晚期直肠癌临床研究  

Clinical study of capecitabine combined with platinum for concurrent radiotherapy and chemotherapy in the treatment of advanced rectal cancer

作　　者：丁涤非[1] 韩卫[1] 王玉生[1] 

机构地区：[1]解放军第123医院肿瘤科,安徽蚌埠233015

出　　处：《安徽卫生职业技术学院学报》2016年第6期29-30,共2页Journal of Anhui Health Vocational & Technical College

摘　　要：目的:探讨卡培他滨联合铂类同步放化疗方案治疗晚期直肠癌临床效果及安全性。方法:选取晚期直肠癌患者共100例,以随机区组法分为对照组(50例)和试验组(50例),分别在同步放疗基础上加用卡培他滨单药化疗和与奥沙利铂联用化疗;比较两组患者临床疗效、生活质量改善率及不良反应发生率等。结果:试验组患者临床疗效和生活质量改善率显著高于对照组(P<0.05);试验组患者消化道反应和骨髓抑制发生率显著低于对照组(P<0.05);试验组患者手足综合征发生率显著高于对照组(P<0.05)。结论:卡培他滨联合铂类同步放化疗方案治疗晚期直肠癌可有效延缓病情进展,提高生活质量,并有助于降低消化道和骨髓抑制不良反应。Objective：To investigate the clinical effects and safety of capecitabine combined with platinum for concurrent radiotherapy and chemotherapy in the treatment of advanced rectal cancer.Methods：lO0 patients with advanced rectal cancer were chosen and randomly divided into two groups including control group （50 patients） with eapecitabine used alone and treatment group （50 patients） with capecitabine combined with platinum for concurrent radiotherapy and chemotherapy; and the clinical effects, the improvement rate of quality of life and the incidence of adverse reactions of both groups were compared.Results：The clinical effects and the improvement rate of quality of life of treatment group after treatment was significant better than control group （ P〈0.05 ） .The incidence of digestive tract reaction and bone marrow suppression of treatment group after treatment was significant lower than control group （ P〈0.05 ） .The incidence of hand foot syndrome of treatment group after treatment was significant higher than control group （ P〈 0.05 ） .Conclusion：Capecitabine combined with platinum for concurrent radiotherapy and chemotherapy in the treatment of advanced rectal cancer can efficiently delay the disease progress, higher the quality of life and be helpfl to reduce the risk of digestive tract and bone marrow suppression.

关 键 词：卡培他滨 铂类 放化疗 晚期直肠癌 

分 类 号：R735.3[医药卫生—肿瘤]